Women's Health

A Response to “We Can Do Better: Educating on Perimenopause and Menopause Is a Good Thing,” Published in November 2025

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Reevaluating menopause hormone therapy myths, risks, timing, and access.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.

The Medications Optimizing Maternal Safety (MOMS) program offers vital support to pregnant patients through community pharmacies.

Recent research reveals no link between menopause hormone therapy and dementia risk, urging further studies to clarify its effects on cognitive health.

A study determined that lifestyle factors and comorbidities were more likely to be associated with the onset of diabetes.

Explaining megestrol acetate's dual role in managing symptoms and enhancing treatment efficacy for estrogen receptor–positive breast cancer.

The guidelines are believed to promote screening adherence by providing women with a more comfortable, accessible, and less stressful testing option.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

Continuous glucose monitoring (CGM) significantly reduces the risk of high birth weight in babies born to mothers with gestational diabetes.

COVID-19 vaccination significantly lowers severe illness and preterm birth risks for pregnant individuals.

Pharmacists can educate patients about FluMist for at-home administration and opioid labeling changes.

The FDA-approved flibanserin represents the first and only once-daily oral pill for postmenopausal women with hypoactive sexual desire disorder.

Pharmacists play a vital role in preventing maternal and neonatal mortality by understanding pregnancy-specific medication needs and emergency care strategies.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.

New studies reveal a modest, temporary increase in breast cancer risk linked to hormonal contraceptives, emphasizing the need for informed patient counseling.

Particularly, younger women with chronic kidney disease (CKD) experienced the greatest survival disadvantage.

Pharmacists Can Educate Patients About Symptoms of Menopause, Associated Chronic Conditions, and Management Options

Natural strategies and OTC options can help manage menopause symptoms, from hot flashes to mood changes, for a smoother transition.

Elinzanetant Showed Smaller Reductions in Bone Mineral Density Than Placebo